“The unique fusion of individual innovative technologies will provide a novel diagnostic tool leading to a better understanding of the underlying pathophysiology of rare anaemia.”

Lars Kaestner, Coordinator of CoMMiTMenT


With the proposed novel methodology (µCOSMOS), CoMMiTMenT will identify and characterise the molecular causes of RBC channelopathies and channel-linked disorders and propose personalised pharmacological interventions to counteract the abnormal function of ion transporters. This bench-to-bedside approach will be verified by an accompanying proof-of-concept test. CoMMiTMenT will have access to a phase II clinical study of patients with sickle cell disease (performed and funded outside of CoMMiTMenT), in which the concept of a personalized dose (not a personalized "Cocktail" of drugs) can be tested. With respect to sickle cell disease, it is possible that the transition into clinical application will be reached within CoMMiTMenT.